🧬Tidera Health
⚕️

Educational tool only. Does not confirm eligibility or provide medical advice. Always consult your physician before pursuing any trial.

NephrologyICD-10: N18

Find Recruiting Clinical Trials for Chronic Kidney Disease

Search CKD, diabetic nephropathy, IgA nephropathy, and FSGS trials — matched to your eGFR, proteinuria, and kidney disease type.

🔍 Search Chronic Kidney Disease Trials →

About Chronic Kidney Disease

Chronic kidney disease (CKD) affects approximately 37 million Americans (15% of adults) and is defined as abnormalities of kidney structure or function present for more than 3 months. It is staged by eGFR (estimated glomerular filtration rate) from G1 (eGFR ≥90) through G5 (eGFR <15, kidney failure). Diabetic nephropathy and hypertensive nephropathy are the leading causes. CKD is a major cardiovascular risk factor and leads to end-stage renal disease (ESRD) requiring dialysis or transplantation in a subset of patients. SGLT2 inhibitors (dapagliflozin, empagliflozin) have recently demonstrated kidney-protective effects across CKD causes.

What Types of Chronic Kidney Disease Clinical Trials Exist?

CKD trials span multiple etiologies and stages. IgA nephropathy (IgAN) — the most common primary glomerulonephritis — has a newly approved targeted therapy (sparsentan, budesonide) and multiple active trials targeting the complement pathway, APRIL/BAFF, and endothelin. FSGS (focal segmental glomerulosclerosis) trials test sparsentan and novel agents. Diabetic nephropathy trials extend SGLT2 inhibitor and non-steroidal MRA (finerenone) data. General CKD trials test RAAS optimization, anti-inflammatory approaches, and novel kidney-protective agents. eGFR, urine protein-to-creatinine ratio (UPCR), and kidney biopsy findings are standard eligibility variables.

Find Recruiting Chronic Kidney Disease Trials Near You

Enter your profile and we'll search ClinicalTrials.gov in real time — matching trials to your age, location, and treatment history. Free, no account required.

Search Chronic Kidney Disease Trials →

Data from ClinicalTrials.gov · Updated in real time · Educational use only

Frequently Asked Questions

What clinical trials are available for chronic kidney disease?▾
Recruiting CKD trials include IgA nephropathy-targeted therapies (complement inhibitors, APRIL/BAFF inhibitors, budesonide formulations), FSGS trials (sparsentan combinations), SGLT2 inhibitor extension studies across CKD causes, non-steroidal MRA trials (finerenone extension), and novel anti-fibrotic/anti-inflammatory kidney protection studies.
What eGFR do I need for CKD clinical trials?▾
eGFR eligibility thresholds vary significantly by trial. Most preservation trials require eGFR ≥20–25 mL/min/1.73m² (not yet on dialysis). Some IgA nephropathy trials enroll eGFR ≥30. End-stage renal disease trials specifically enroll dialysis patients. Know your most recent eGFR value — it is the primary eligibility determinant.
How does proteinuria affect CKD trial eligibility?▾
Proteinuria (protein in urine) measured as UPCR (urine protein-to-creatinine ratio) or 24-hour urine protein is a standard eligibility and endpoint measure. Most CKD trials targeting progressive disease require elevated proteinuria (UPCR ≥0.5–1.0 g/g), confirming active kidney injury. Proteinuria-lowering is often a primary or secondary trial endpoint.

Related Conditions

Type 2 DiabetesType 1 DiabetesLupus (SLE)

Data source: All clinical trial information is sourced from ClinicalTrials.gov, the official U.S. registry maintained by the National Library of Medicine. Tidera Health is an independent educational platform and is not affiliated with ClinicalTrials.gov or the National Library of Medicine. Always verify trial details directly with the research coordinator or your physician.